Redx Pharma Plc and Jounce Therapeutics, Inc. have announced an all-share merger to form a $425m firm focused on targeted therapeutics for the treatment of cancer and fibrotic diseases across both small- and large-molecule modalities.
By merger completion, Jounce should have $155m in cash and equivalents which, net of tail and closing costs, would leave...
Welcome to Scrip
Create an account to read this article
Already a subscriber?